0HQ8 Stock Chart & Stats
kr28.96
kr0.32(1.18%)
At close: 4:00 PM EDT
kr28.96
kr0.32(1.18%)
Day’s Range― - ―
52-Week Rangekr23.80 - kr34.12
Previous CloseN/A
Volume2.99K
Average Volume (3M)23.94K
Market Cap
kr9.18B
Enterprise Valuekr12.01B
Total Cash (Recent Filing)kr858.00M
Total Debt (Recent Filing)kr5.35B
Price to Earnings (P/E)25.4
Beta0.72
Next Earnings
Jan 28, 2027EPS Estimate
0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.33
Shares Outstanding254,152,370
10 Day Avg. Volume30,214
30 Day Avg. Volume23,940
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.17
Price to Sales (P/S)0.79
P/FCF Ratio11.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr39.00Price Target Upside34.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.74
Revenue Forecast (FY)kr11.32B
Bulls Say, Bears Say
Bulls Say
Structural Care DemandUnderlying demand is supported by a growing number of patients requiring care, which can make Arjo’s products relevant across economic cycles. This structural need, combined with its focus on acute and long-term care, supports durable market opportunity and recurring replacement and service demand.
Global Operating PlatformArjo’s established international platform provides broad customer access, operational scale, and diversification across healthcare markets. Its presence in more than 100 countries and focus on multiple care settings can support product adoption, service reach, and resilience as regional demand patterns vary.
Cash Flow And LeverageCurrent cash generation and improving leverage provide financial flexibility to support operations, investment, and strategic initiatives. Stronger free cash flow also gives Arjo more capacity to manage restructuring, fund commercial priorities, and reduce balance-sheet pressure over the medium term.
Bears Say
Compressed ProfitabilityProfitability remains materially below prior years, limiting the earnings produced from Arjo’s revenue base and equity capital. Lower margins can reduce resilience to cost inflation or pricing pressure, while modest ROE suggests the company is not yet converting its capital base into returns as efficiently as before.
Restructuring BurdenThe operating-model changes require substantial restructuring and role reshuffling, creating execution demands and near-term cost pressure. Although intended to improve EBIT over time, the transition could distract management, disrupt processes, and delay the realization of the planned benefits during the coming 18 months.
Uneven Cash DurabilityRecent cash generation is strong, but the historical record shows meaningful volatility and incomplete conversion of accounting earnings into free cash flow. That unevenness can constrain internally funded investment and makes future cash performance more dependent on working capital and operating execution.
Arjo AB News
0HQ8 FAQ
What was Arjo AB Class B’s price range in the past 12 months?
Arjo AB Class B lowest share price was kr23.80 and its highest was kr34.12 in the past 12 months.
What is Arjo AB Class B’s market cap?
Arjo AB Class B’s market cap is kr9.18B.
When is Arjo AB Class B’s upcoming earnings report date?
Arjo AB Class B’s upcoming earnings report date is Jan 28, 2027 which is in 88 days.
How were Arjo AB Class B’s earnings last quarter?
Arjo AB Class B released its earnings results on Oct 22, 2026. The company reported kr0.21 earnings per share for the quarter, missing the consensus estimate of kr0.392 by -kr0.182.
Is Arjo AB Class B overvalued?
According to Wall Street analysts Arjo AB Class B’s price is currently Undervalued.
Does Arjo AB Class B pay dividends?
Arjo AB Class B does not currently pay dividends.
What is Arjo AB Class B’s EPS estimate?
Arjo AB Class B’s EPS estimate is 0.6.
How many shares outstanding does Arjo AB Class B have?
Arjo AB Class B has 254,152,370 shares outstanding.
What happened to Arjo AB Class B’s price movement after its last earnings report?
Arjo AB Class B reported an EPS of kr0.21 in its last earnings report, missing expectations of kr0.392. Following the earnings report the stock price went up 15.726%.
Which hedge fund is a major shareholder of Arjo AB Class B?
Currently, no hedge funds are holding shares in GB:0HQ8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Arjo AB Class B
Arjo AB (publ) is a global leader in providing medical devices and innovative solutions tailored for patients experiencing limited mobility and age-related health conditions. Operating across North America, Western Europe, and other international markets, the company's comprehensive offerings span safe patient handling, hygiene and disinfection products, specialized medical beds, and technologies for the prevention and treatment of pressure injuries, leg ulcers, deep vein thrombosis, and edema. They also supply equipment for obstetric and cardiac diagnostics. Complementing its product range, Arjo delivers valuable services such as specialized room assessments for dementia and bariatric care, clinical consulting, equipment maintenance, and flexible rental and financing options. Their diverse client base comprises both private and public institutions engaged in acute and long-term healthcare. Founded in 1957, Arjo AB (publ) is headquartered in Malmö, Sweden.
0HQ8 Company Deck
0HQ8 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive, supported by 6% organic growth, stronger gross profit and adjusted EBIT, improved reported margins, higher operating cash flow, and lower leverage. Management also highlighted strong momentum in patient handling, North America, and Europe, along with a SEK 350 million EBIT improvement plan. Offsetting issues included higher restructuring costs, weaker quarterly performance in international and distributor-led markets, less favorable working capital, negative investment cash flow, revaluation losses, and uncertainty around the flu season's effect on the fourth quarter.View all GB:0HQ8 earnings summaries0HQ8 Stock 12 Month Forecast
Average Price Target
kr39.00
▲(34.67% Upside)
Technical Analysis
AddLife AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―
Sedana Medical AB
―
Asker Healthcare Group AB
―